CipAir 应用程序在印度进行哮喘筛查,旨在解决诊断不足问题和改善护理。 Cipla launches CipAir app for asthma screening in India, aiming to tackle underdiagnosis and improve care.

印度CipAir制药公司引进了CipAir, 这是印度首次哮喘筛查的移动应用程序, 哮喘影响着3 430万人。 Indian pharmaceutical company Cipla has introduced CipAir, a mobile app for initial asthma screening in India, where asthma affects 34.3 million people. 该应用程序的目标是诊断不足和治疗不足,导致死亡率和残疾率高于全球平均水平。 The app targets underdiagnosis and undertreatment, which contribute to higher mortality and disability rates compared to global averages. 在Android上,CipAir不久将启动iOS系统,目的是加强诊断和病人护理。 Available on Android, CipAir will soon be launched for iOS, aiming to enhance diagnostics and patient care.